Clinical Trials Directory

Trials / Completed

CompletedNCT00394537

Labetalol to Prevent Hypertension and Tachycardia During Fiberoptic Bronchoscopy

Status
Completed
Phase
Phase 4
Study type
Interventional
Enrollment
72 (estimated)
Sponsor
Rabin Medical Center · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

Passing a bronchoscope through the airways frequently causes a stress response even though patients are sedated. This stress response is usually an increase in pulse and blood pressure, which may have undesirable effects on the heart and circulation. We plan to give patients labetalol (a beta blocker which reduces pulse and blood pressure) in addition to normal sedation, to patients undergoing bronchoscopy in our department.

Conditions

Interventions

TypeNameDescription
DRUGLabetalol 10mg iv

Timeline

Completion
2007-05-01
First posted
2006-11-01
Last updated
2007-06-06

Locations

1 site across 1 country: Israel

Source: ClinicalTrials.gov record NCT00394537. Inclusion in this directory is not an endorsement.